Nealbarbital
| Nealbarbital | |
|---|---|
| Nealbarbital.svg | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Nealbarbital is a barbiturate derivative that has been used in the field of medicine for its sedative and hypnotic properties. It is a central nervous system depressant that works by enhancing the activity of the neurotransmitter gamma-aminobutyric acid (GABA).
Pharmacology[edit]
Nealbarbital acts on the GABA_A receptor, increasing the duration of chloride channel opening and thus enhancing the inhibitory effect of GABA in the central nervous system. This results in a calming effect, making it useful for treating conditions such as insomnia and anxiety.
Medical Uses[edit]
Nealbarbital has been used primarily as a sedative and hypnotic agent. It is prescribed for short-term management of insomnia and for preoperative sedation. Due to its potential for dependence and tolerance, its use is generally limited to short durations.
Side Effects[edit]
Common side effects of Nealbarbital include drowsiness, dizziness, and headache. More serious side effects can include respiratory depression, hypotension, and allergic reactions. Long-term use can lead to dependence and withdrawal symptoms.
History[edit]
Nealbarbital was first synthesized in the early 20th century as part of the development of barbiturates for medical use. It was introduced into clinical practice as a safer alternative to earlier sedatives.
Chemical Properties[edit]
Nealbarbital is a barbiturate with a chemical structure that includes a pyrimidine ring. Its molecular formula is C12H14N2O3.
